Esther Virginia Rettig, MD | |
901 N Main St, Mcpherson, KS 67460-2841 | |
(620) 245-0556 | |
(620) 245-0503 |
Full Name | Esther Virginia Rettig |
---|---|
Gender | Female |
Speciality | Ophthalmology |
Experience | 31 Years |
Location | 901 N Main St, Mcpherson, Kansas |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1497802722 | NPI | - | NPPES |
100291310C | Medicaid | KS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | 0427129KS (Kansas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Mcpherson Hospital | Mcpherson, KS | Hospital |
Salina Surgical Hospital | Salina, KS | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Dr Esther Rettig Md Pa | 8123160454 | 2 |
News Archive
Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.
The World health Organization calls depression "the leading cause of disability worldwide," causing more years of disability than cancer, HIV/AIDS, and cardiovascular and respiratory diseases combined.
In an effort to develop therapeutic remedies for multiple sclerosis, scientists debate two possible interventional approaches - but they're on opposite sides of the spectrum. Researchers at Wayne State University's School of Medicine, however, have reached a definitive conclusion as to which approach is correct, putting an end to a long-disputed issue.
A new chemical synthesis strategy to harvest the rich information found in natural products - organic compounds isolated from natural sources - has led to the identification of novel, simpler derivatives with potential to selectively protect neurons, important for neurodegenerative diseases like Alzheimer's disease, or to prevent the immune system from rejecting organ transplants, according to a Baylor University-led study.
› Verified 7 days ago
Entity Name | Dr Esther Rettig Md Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1184952889 PECOS PAC ID: 8123160454 Enrollment ID: O20100125000155 |
News Archive
Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.
The World health Organization calls depression "the leading cause of disability worldwide," causing more years of disability than cancer, HIV/AIDS, and cardiovascular and respiratory diseases combined.
In an effort to develop therapeutic remedies for multiple sclerosis, scientists debate two possible interventional approaches - but they're on opposite sides of the spectrum. Researchers at Wayne State University's School of Medicine, however, have reached a definitive conclusion as to which approach is correct, putting an end to a long-disputed issue.
A new chemical synthesis strategy to harvest the rich information found in natural products - organic compounds isolated from natural sources - has led to the identification of novel, simpler derivatives with potential to selectively protect neurons, important for neurodegenerative diseases like Alzheimer's disease, or to prevent the immune system from rejecting organ transplants, according to a Baylor University-led study.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Esther Virginia Rettig, MD 901 N Main St, Mcpherson, KS 67460-2841 Ph: (620) 245-0556 | Esther Virginia Rettig, MD 901 N Main St, Mcpherson, KS 67460-2841 Ph: (620) 245-0556 |
News Archive
Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.
The World health Organization calls depression "the leading cause of disability worldwide," causing more years of disability than cancer, HIV/AIDS, and cardiovascular and respiratory diseases combined.
In an effort to develop therapeutic remedies for multiple sclerosis, scientists debate two possible interventional approaches - but they're on opposite sides of the spectrum. Researchers at Wayne State University's School of Medicine, however, have reached a definitive conclusion as to which approach is correct, putting an end to a long-disputed issue.
A new chemical synthesis strategy to harvest the rich information found in natural products - organic compounds isolated from natural sources - has led to the identification of novel, simpler derivatives with potential to selectively protect neurons, important for neurodegenerative diseases like Alzheimer's disease, or to prevent the immune system from rejecting organ transplants, according to a Baylor University-led study.
› Verified 7 days ago